![]() |
市場調查報告書
商品編碼
1481780
全球腫瘤學伴隨診斷測試市場研究報告 - 2024 年至 2032 年行業分析、規模、佔有率、成長、趨勢和預測Global Companion Diagnostic Tests in Oncology Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
預計到 2032 年,全球腫瘤市場伴隨診斷測試的市場規模將從 2023 年的 58.9 億美元達到近 139.9 億美元,2024-2032 年研究期間複合年成長率為 10.09%。
腫瘤學中的伴隨診斷測試旨在識別與患者的癌症診斷或預後相關的特定生物標記或分子標靶。這些測試與標靶癌症療法一起使用,以個性化治療決策、預測治療反應並監測疾病進展。這些測試分析生物樣本,如組織活體組織切片、血液樣本或循環腫瘤 DNA,以檢測基因突變、基因擴增、蛋白質表現量或其他指示癌症亞型、分期或治療反應的分子變化。透過提供有關患者腫瘤生物學的可行資訊,伴隨診斷測試使腫瘤學家能夠在精準腫瘤學實踐中製定治療策略、最佳化治療選擇並改善患者的治療效果。
全球癌症的流行,加上分子生物學和基因組學的進步,正在推動用於個人化癌症治療的伴隨診斷測試的開發和採用。此外,對精準醫療和基於價值的醫療保健的日益重視推動了對輔助診斷測試的需求,這些測試有助於最佳化治療結果、最大限度地減少不良反應並降低醫療成本。此外,監管機構簡化藥物核准流程和鼓勵標靶治療開發的措施正在推動對伴隨診斷測試開發和商業化的投資。此外,製藥公司、診斷實驗室和研究機構之間的合作和夥伴關係推動創新並加速針對新興生物標記和治療標靶的伴隨診斷測試的開發。此外,液體活體組織切片和新一代定序 (NGS) 技術的日益普及正在擴大伴隨診斷測試的範圍和能力,從而能夠對腫瘤進行非侵入性和全面的分析,以實現精準腫瘤學應用。然而,不斷變化的監管環境和報銷挑戰可能會對未來幾年腫瘤學市場成長的伴隨診斷測試提出挑戰。
研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外,這些工具還對全球腫瘤學伴隨診斷測試市場的每個細分市場進行了包容性評估。腫瘤學產業伴隨診斷測試的成長和趨勢為這項研究提供了整體方法。
腫瘤學市場報告中的伴隨診斷測試的這一部分提供了國家和區域層面細分市場的詳細資料,從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。
本節涵蓋區域前景,重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲腫瘤學伴隨診斷測試市場當前和未來的需求。此外,該報告重點關注所有主要地區各個應用領域的需求、估計和預測。
該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。腫瘤伴隨診斷測試市場的主要參與者包括 Abbott、F. Hoffmann-LA Roche AG、Genomic Health, Inc.、Qiagen、Agilent Technologies, Inc.、Agendia NV、bioMerieux SA、Illumina, Inc.、Siemens Healthineers、賽默飛世爾科技公司、BioGenex。本節包含競爭格局的整體視圖,包括各種策略發展,例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。
如果您有任何客製化要求,請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。
The global demand for Companion Diagnostic Tests in Oncology Market is presumed to reach the market size of nearly USD 13.99 Billion by 2032 from USD 5.89 Billion in 2023 with a CAGR of 10.09% under the study period 2024 - 2032.
Companion diagnostic tests in oncology are designed to identify specific biomarkers or molecular targets associated with a patient's cancer diagnosis or prognosis. These tests are used with targeted cancer therapies to personalize treatment decisions, predict treatment response, and monitor disease progression. These tests analyze biological samples such as tissue biopsies, blood samples, or circulating tumor DNA to detect genetic mutations, gene amplifications, protein expression levels, or other molecular alterations indicative of cancer subtype, stage, or treatment response. By providing actionable information about a patient's tumor biology, companion diagnostic tests enable oncologists to tailor treatment strategies, optimize therapy selection, and improve patient outcomes in precision oncology practice.
The spurring prevalence of cancer worldwide, coupled with advancements in molecular biology and genomics, is driving the development and adoption of companion diagnostic tests for personalized cancer treatment. Additionally, the escalating emphasis on precision medicine and value-based healthcare drives demand for companion diagnostic tests that help optimize treatment outcomes, minimize adverse effects, and reduce healthcare costs. Moreover, regulatory agencies' initiatives to streamline drug approval processes and encourage the development of targeted therapies are driving investment in companion diagnostic test development and commercialization. Furthermore, collaborations and partnerships between pharmaceutical companies, diagnostic laboratories, and research institutions drive innovation and accelerate the development of companion diagnostic tests for emerging biomarkers and therapeutic targets. Additionally, the growing adoption of liquid biopsy and next-generation sequencing (NGS) technologies is expanding the scope and capabilities of companion diagnostic tests, enabling non-invasive and comprehensive profiling of tumors for precision oncology applications. However, the evolving regulatory landscape and reimbursement challenges may challenge the companion diagnostic tests in oncology market growth in the coming years.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of companion diagnostic tests in oncology. The growth and trends of companion diagnostic tests in oncology industry provide a holistic approach to this study.
This section of the companion diagnostic tests in oncology market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
This section covers the regional outlook, which accentuates current and future demand for the Companion Diagnostic Tests in Oncology market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Companion Diagnostic Tests in Oncology market include Abbott, F. Hoffmann-LA Roche AG, Genomic Health, Inc., Qiagen, Agilent Technologies, Inc., Agendia N.V., bioMerieux SA, Illumina, Inc., Siemens Healthineers, Thermo Fisher Scientific Inc., BioGenex. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.